Genmab — November 2019
-
But CD38 still remains on the myeloma cell, however at lower levels. So the target is still relevant. And we feel there's sufficient retained expression for most patients that we can still go at that target but with these enhanced antibodies. So there would really be an attempt to rescue patients who failed a frontline standard care agent.
-
-
a small new trial using BMS-986253 / HuMax-IL8 for NSCLC https://clinicaltrials.gov/ct2/show/NCT04123379
-
a saw from this message from a Belgian University hospital that one of the area's BMS-986253 is used is Dermatological tumors/ melanoma https://www.uzgent.be/nl/zorgaanbod/mdspecialismen/Geneesmiddelenonderzoek/Lopende-studies/Paginas/Indicatoren-dermatologische-tumoren.aspx (clinicaltrials only mentioned 'advanced cancers' https://www.clinicaltrials.gov/ct2/show/study/NCT03400332?term=BMS-986253&show_locs=Y#locn )
-
Så er de vist oppe igen. Kursen hoppede lige.
-
Har de fået deres system fra den samme leverandør som Skat?
-
Pefekt. Så kan de lige smide IC4 togene med ind i erstatningskravet. Rart at have det hele samlet et sted
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind